Had to ask another question, here's Claude's answer.
Please take in consideration that AI answers are based on historical events, and if Dr. Jay is correct saying that Leronlimab will have its own chapter in medical history, we're talking about unproven grounds and AI's lack of fantasy would be the bottle neck:
According to latest financial filings, which other big pharma companies would have the capacity for a deal that size? And which impact on the buyout price may a bidding war including several suitors have?
Based on current balance sheets, several big pharma peers have real capacity for a deal that size — though with very different comfort levels:
**Strongest candidates**
- **Johnson & Johnson** — the cleanest balance sheet of the group: $20.4B in cash against $39.1B in total debt, [Investing.com](https://www.investing.com/equities/johnson-johnson-balance-sheet) plus a $201B asset base. An outside analysis (Stifel, via BioSpace) pegs J&J's "comfortable" M&A firepower at $59 billion, [BioSpace](https://www.biospace.com/business/the-top-big-pharmas-have-1-2t-in-stretch-m-a-firepower-available) though the same analysis notes J&J has historically been conservative, reluctant to use its full balance sheet capacity. [BioSpace](https://www.biospace.com/business/the-top-big-pharmas-have-1-2t-in-stretch-m-a-firepower-available)
- **Roche** — similarly rated at $60 billion in comfortable firepower, [BioSpace](https://www.biospace.com/business/the-top-big-pharmas-have-1-2t-in-stretch-m-a-firepower-available) with the same conservative tendency noted.
- **Novo Nordisk** — tops the list at $63 billion comfortable, $113 billion at "stretch", [BioSpace](https://www.biospace.com/business/the-top-big-pharmas-have-1-2t-in-stretch-m-a-firepower-available) backed by Ozempic/Wegovy cash flow — though its market cap has fallen sharply over the past year, which changes the equity-financing math.
- **Eli Lilly** — technically already leveraged ($54.9B of debt) [Stock Titan](https://www.stocktitan.net/sec-filings/LLY/10-q-eli-lilly-co-quarterly-earnings-report-f324849e50d6.html) and mid-spree on smaller bolt-ons, but its ~$1.1 trillion market cap [Yahoo Finance](https://finance.yahoo.com/quote/LLY/) gives it enormous equity currency; a $40-60B deal would be a small dilution hit relative to its size.
**More constrained right now**
- **Pfizer** — despite just proving it'll fight for deals (see below), its market cap has shrunk to roughly $145-155B while debt sits near $64.7 billion. [StockAnalysis](https://stockanalysis.com/stocks/pfe/statistics/) A $40-60B deal would be unusually aggressive relative to its own size today.
- **AbbVie** — already highly leveraged, just issued $8B in new senior notes in March 2026 [Stock Titan](https://www.stocktitan.net/sec-filings/ABBV/10-q-abb-vie-inc-quarterly-earnings-report-44f9bbbf4f7c.html) and has a pending $10.9B Apogee acquisition. [Stock Titan](https://www.stocktitan.net/sec-filings/ABBV/10-q-abb-vie-inc-quarterly-earnings-report-44f9bbbf4f7c.html) Room exists, but less than peers.
- **Novartis** — net debt already jumped to $38.1 billion [SEC.gov](https://www.sec.gov/Archives/edgar/data/1114448/000111444826000010/a260428-99_2.htm) after the $12B Avidity Biosciences deal earlier in 2026, so a big new deal would mean stacking leverage further.
**Bidding wars: the effect on price**
The clearest recent template is Pfizer vs. Novo Nordisk for **Metsera** (2025): Pfizer's initial deal was $4.9 billion in cash, up to $7.3 billion including contingent payments. [Bloomberg](https://www.bloomberg.com/news/articles/2025-11-08/pfizer-sweetens-its-offer-for-metsera-in-bidding-war-against-novo) Once Novo Nordisk jumped in, the price escalated over two weeks to a final $65.60 per share upfront plus up to $20.65 per share via contingent value rights, totaling as much as $86.25 per share, or roughly $10 billion. [Fierce Biotech](https://www.fiercebiotech.com/biotech/pfizer-finalizes-metsera-buy-after-contentious-bidding-war-novo-nordisk) That's more than double the original headline price in under two months.
The general mechanics that drive this:
- **Fiduciary duty forces an auction** — once a second credible bidder appears, the target's board is legally obligated to seek the best price, not just accept the first offer.
- **Deal structure shifts toward certainty** — as competition heats up, upfront cash tends to replace contingent/earnout components, since sellers can demand more certainty when they have leverage.
- **Regulatory risk can decide the "winner" even without the highest bid** — in Metsera's case, antitrust concerns around Novo's structure (weight-loss market overlap with existing Novo drugs) tipped the decision to Pfizer even at a matched price.
- **"Winner's curse" risk** — the winning bidder often ends up overpaying relative to standalone valuation, which is part of why bidding wars make rating agencies and shareholders nervous about the eventual acquirer's leverage.
For a hypothetical $40-60B Merck target, a second serious bidder could plausibly push the final price up 20-40%+ versus a solo negotiation, based on how recent contests in the sector have played out.
Please take in consideration that AI answers are based on historical events, and if Dr. Jay is correct saying that Leronlimab will have its own chapter in medical history, we're talking about unproven grounds and AI's lack of fantasy would be the bottle neck:
According to latest financial filings, which other big pharma companies would have the capacity for a deal that size? And which impact on the buyout price may a bidding war including several suitors have?
Based on current balance sheets, several big pharma peers have real capacity for a deal that size — though with very different comfort levels:
**Strongest candidates**
- **Johnson & Johnson** — the cleanest balance sheet of the group: $20.4B in cash against $39.1B in total debt, [Investing.com](https://www.investing.com/equities/johnson-johnson-balance-sheet) plus a $201B asset base. An outside analysis (Stifel, via BioSpace) pegs J&J's "comfortable" M&A firepower at $59 billion, [BioSpace](https://www.biospace.com/business/the-top-big-pharmas-have-1-2t-in-stretch-m-a-firepower-available) though the same analysis notes J&J has historically been conservative, reluctant to use its full balance sheet capacity. [BioSpace](https://www.biospace.com/business/the-top-big-pharmas-have-1-2t-in-stretch-m-a-firepower-available)
- **Roche** — similarly rated at $60 billion in comfortable firepower, [BioSpace](https://www.biospace.com/business/the-top-big-pharmas-have-1-2t-in-stretch-m-a-firepower-available) with the same conservative tendency noted.
- **Novo Nordisk** — tops the list at $63 billion comfortable, $113 billion at "stretch", [BioSpace](https://www.biospace.com/business/the-top-big-pharmas-have-1-2t-in-stretch-m-a-firepower-available) backed by Ozempic/Wegovy cash flow — though its market cap has fallen sharply over the past year, which changes the equity-financing math.
- **Eli Lilly** — technically already leveraged ($54.9B of debt) [Stock Titan](https://www.stocktitan.net/sec-filings/LLY/10-q-eli-lilly-co-quarterly-earnings-report-f324849e50d6.html) and mid-spree on smaller bolt-ons, but its ~$1.1 trillion market cap [Yahoo Finance](https://finance.yahoo.com/quote/LLY/) gives it enormous equity currency; a $40-60B deal would be a small dilution hit relative to its size.
**More constrained right now**
- **Pfizer** — despite just proving it'll fight for deals (see below), its market cap has shrunk to roughly $145-155B while debt sits near $64.7 billion. [StockAnalysis](https://stockanalysis.com/stocks/pfe/statistics/) A $40-60B deal would be unusually aggressive relative to its own size today.
- **AbbVie** — already highly leveraged, just issued $8B in new senior notes in March 2026 [Stock Titan](https://www.stocktitan.net/sec-filings/ABBV/10-q-abb-vie-inc-quarterly-earnings-report-44f9bbbf4f7c.html) and has a pending $10.9B Apogee acquisition. [Stock Titan](https://www.stocktitan.net/sec-filings/ABBV/10-q-abb-vie-inc-quarterly-earnings-report-44f9bbbf4f7c.html) Room exists, but less than peers.
- **Novartis** — net debt already jumped to $38.1 billion [SEC.gov](https://www.sec.gov/Archives/edgar/data/1114448/000111444826000010/a260428-99_2.htm) after the $12B Avidity Biosciences deal earlier in 2026, so a big new deal would mean stacking leverage further.
**Bidding wars: the effect on price**
The clearest recent template is Pfizer vs. Novo Nordisk for **Metsera** (2025): Pfizer's initial deal was $4.9 billion in cash, up to $7.3 billion including contingent payments. [Bloomberg](https://www.bloomberg.com/news/articles/2025-11-08/pfizer-sweetens-its-offer-for-metsera-in-bidding-war-against-novo) Once Novo Nordisk jumped in, the price escalated over two weeks to a final $65.60 per share upfront plus up to $20.65 per share via contingent value rights, totaling as much as $86.25 per share, or roughly $10 billion. [Fierce Biotech](https://www.fiercebiotech.com/biotech/pfizer-finalizes-metsera-buy-after-contentious-bidding-war-novo-nordisk) That's more than double the original headline price in under two months.
The general mechanics that drive this:
- **Fiduciary duty forces an auction** — once a second credible bidder appears, the target's board is legally obligated to seek the best price, not just accept the first offer.
- **Deal structure shifts toward certainty** — as competition heats up, upfront cash tends to replace contingent/earnout components, since sellers can demand more certainty when they have leverage.
- **Regulatory risk can decide the "winner" even without the highest bid** — in Metsera's case, antitrust concerns around Novo's structure (weight-loss market overlap with existing Novo drugs) tipped the decision to Pfizer even at a matched price.
- **"Winner's curse" risk** — the winning bidder often ends up overpaying relative to standalone valuation, which is part of why bidding wars make rating agencies and shareholders nervous about the eventual acquirer's leverage.
For a hypothetical $40-60B Merck target, a second serious bidder could plausibly push the final price up 20-40%+ versus a solo negotiation, based on how recent contests in the sector have played out.
7
